Core D: Neuroimaging Core

神经影像核心摘要 ABC-DS 神经影像核心，由博士领导。 Adam Brickman 和 Brad Christian 将应用最先进的技术 正电子发射断层扫描（PET）和磁共振成像（MRI）神经影像技术 根据当前数据对唐氏综合症 (DS) 中的淀粉样蛋白、tau 蛋白和神经变性 (AT(N)) 进行定量 阿尔茨海默病 (AD) 的病理生理学模型以及相关的脑血管、微观结构、 和功能性生物标志物。神经影像核心的具体目标是：(1) 监督协调一致的 在 8 个临床表现地点采集 PET 和 MRI 数据； (2) 量化主要结果 每种神经影像学方式的测量； (3)将处理后的神经影像数据整合到ABC-DS中 支持拟议项目的数据库； (4) 提供精心策划的主要结果变量和原始变量 向更广泛的科学界提供神经影像数据。整体扫描协议将遵循已制定的协议 由阿尔茨海默病神经影像计划 (ADNI) 进行 MRI（结构和功能）和 PET（淀粉样蛋白、 tau、FDG）。结果变量由特定于模态的分析节点得出，并对每种模态进行分析 由具有神经影像生物标志物专业知识的单一实验室进行。核心将利用 NIA 赞助的 目前支持正在进行的大规模 AD 神经影像计划的资源（例如 ADNI、Dominantly 继承阿尔茨海默病网络（DIAN））提供一个完全开发的数据访问管道，鼓励科学 DS 神经影像生物标志物的研究。

Neuroimaging Core Abstract The ABC-DS Neuroimaging Core, led by Drs. Adam Brickman and Brad Christian, will apply state-of-the art positron emission tomography (PET) and magnetic resonance imaging (MRI) neuroimaging techniques to quantitate amyloid, tau, and neurodegeneration (AT(N)) in Down syndrome (DS) according to current pathophysiological models of Alzheimer’s disease (AD) together with related cerebrovascular, microstructural, and functional biomarkers. The specific aims of the Neuroimaging Core are to: (1) oversee the harmonized acquisition of PET and MRI data at each of the 8 clinical performance sites; (2) quantitate primary outcome measures for each neuroimaging modality; (3) integrate the processed neuroimaging data into a ABC-DS database to support the proposed projects; and (4) provide curated primary outcome variables and raw neuroimaging data to the wider scientific community. The overall scanning protocols will follow those developed by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) for MRI (structural and functional) and PET (amyloid, tau, FDG). The outcome variables are derived by modality-specific analytic nodes, with each modality analyzed by a single laboratory with expertise in that neuroimaging biomarker. The Core will utilize NIA-sponsored resources that currently support ongoing large-scale AD neuroimaging initiatives (e.g. ADNI, Dominantly Inherited Alzheimer Network (DIAN)) to provide a fully developed data-access pipeline that encourages scientific investigation of neuroimaging biomarkers in DS.